Showing 7761-7770 of 9807 results for "".
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) f
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4
- Deloitte Launches 'Illustrate Change' Medical Illustration Libraryhttps://practicaldermatology.com/news/deloitte-launches-illustrate-change-medical-illustration-library/2461794/Deloitte is launching "Illustrate Change," a project that seeks to increase representation in medical i
- Dr. Michele L. Ramien Takes the Helm as President of the Canadian Dermatology Associationhttps://practicaldermatology.com/news/dr-michele-l-ramien-takes-the-helm-as-president-of-the-canadian-dermatology-association/2461789/Dr. Michele L. Ramien is the new president of The Canadian Dermatology Association (CDA). “I want to increase engagement amongst our members by re-imagining how our community interacts so that - united - we are ready to accomplish all the work we need to do,” says Dr.
- Belotero Balance (+) Restores Volume to Under-eye Hollowshttps://practicaldermatology.com/news/belotero-balance-restores-volume-to-under-eye-hollows/2461782/Belotero Balance® (+) corrects volume loss in the infraorbital hollow area, according to new data from Merz Aesthetics. Merz Aesthetics will submit these data as part of a supplemental Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) this
- Dermwire Chats with HS Docuseries Host Jasmine Ivanna Espyhttps://practicaldermatology.com/news/directors-cut-dermwire-chats-with-hs-docuseries-director-jasmine-ivanna-espy/2461776/Thanks to a burgeoning pipeline of potential new treatments and new education and awareness efforts, hidradenitis suppurativa (HS) is finally getting the attention that it deserves. Novartis recently premiered a new docuseries on life with HS at the 2023 Tribeca Film Fest
- EAACI News: Novel Antibody May Help Treat Melanomahttps://practicaldermatology.com/news/novel-antibody-may-help-treat-melanoma/2461775/A newly discovered antibody may benefit patients with melanoma who do not respond to current immunotherapies, according to a study presented at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Unlike